<i>FGFR1</i> Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas

Jorge S. Reis‐Filho(AstraZeneca (France)), Alan Ashworth(University of California, San Francisco), José Palacios(American University), Chris Jones(North Carolina State University), Peter T. Simpson(The University of Queensland), David Sarrió(Instituto de Investigaciones Biomédicas Sols-Morreale), Sunil R. Lakhani(Sullivan Nicolaides Pathology), Anita Grigoriadis(London Cancer), Marjan Iravani(Institute of Cancer Research), Nicholas C. Turner(Institute of Cancer Research), David Hardisson(Universidad Autónoma de Madrid), Alan Mackay(Institute of Cancer Research), Kay Savage(Institute of Cancer Research), Kerry Fenwick(Institute of Cancer Research), Maryou Ballo Lambros(Institute of Cancer Research), Barbara L. Weber, Tim Dexter(Institute of Cancer Research), Fernando Schmitt(Universidade do Porto)
Clinical Cancer Research
November 15, 2006
10.1158/1078-0432.ccr-06-1164
Cited by 272

Related Papers

Signatures of mutational processes in human cancer
|Nature|2013|10.1k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
The landscape of cancer genes and mutational processes in breast cancer
|Nature|2012|1.7k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k